We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Pdr4.0

PDRN / Polynucleotides (topical) Research

Mostly mechanism / observationalModerate safety

6 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most PDRN / Polynucleotides (topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality randomised trials published 2012–2025 with a typical study size of 27 participants.

Based on 6 studies · 3 RCTs · 263 total participants

Confidence

Moderate

By outcome

Wound & ulcer healing
Mostly mechanism / observational3 studies
Skin healthPossible hydration/skin-quality benefit — established for INJECTABLE polynucleotides; topical-cream evidence is essentially absent (cosmetic) · 8-12 weeks · Possible rejuvenation via collagen stimulation — shown for INJECTABLE PN (comparable to HA filler), not for topical use (cosmetic) · 8-12 weeks
Too few graded studies1 study

Active research area

3 studies in the last 5 years

201220182025

1RCTn=216 · medium study2014

Complete healing was achieved in 18.9% [95% confidence interval (CI) 11.4-26.3] of placebo and in 37.3% (95% CI 28.2-46.3) of PDRN-treated patients (P = .0027).

Squadrito F, Bitto A, Altavilla D, Arcoraci V, De Caridi G, De Feo ME, Corrao S, Pallio G, Sterrantino C, Minutoli L, Saitta A, Vaccaro M, Cucinotta D. · J Clin Endocrinol Metab (2014)

Multicenter randomized double-blind placebo-controlled trial (n=216) of INJECTABLE PDRN (intramuscular + perilesional) for diabetic foot ulcers
PDRN roughly doubled complete ulcer healing vs placebo (37.3% vs 18.9%; HR 2.20)
The strongest controlled PDRN evidence — but for an injected formulation in a wound-healing indication, not cosmetic topical use

View source

2RCTn=27 · very small study2022

Improvements in the visual analog scale and global esthetic improvement scale scores were not significantly different between the PN and HA groups.

Lee YJ, Kim HT, Lee YJ, Paik SH, Moon YS, Lee WJ, Chang SE, Lee MW, Choi JH, Jung JM, Won CH. · J Dermatolog Treat (2022)

Randomized double-blind split-face trial (n=27) of INJECTABLE polynucleotide vs non-crosslinked hyaluronic acid for periocular rejuvenation
Overall esthetic outcomes did not differ significantly between PN and HA — PN was comparable, not superior
PN improved some skin-quality measures more than HA, but this is injection, not a topical product

View source

3Systematic Review2025

Nine studies, of low and moderate quality, were included in this review, describing a population of 219 patients receiving PN treatment.

Lampridou S, Bassett S, Cavallini M, Christopoulos G. · J Cosmet Dermatol (2025)

PRISMA systematic review of polynucleotides in esthetic medicine: nine low-to-moderate-quality studies (219 patients), all INJECTABLE PN
Promising signals for wrinkles, texture, and elasticity, but limited consensus and a call for rigorous, high-quality studies
Two authors disclose industry ties to polynucleotide manufacturers — a conflict-of-interest caveat

View source

4RCTn=20 · very small study2017

No statistically significant difference was found between the control group and the PDRN group in terms of vessel density (P=0.094).

Kim S, Kim J, Choi J, Jeong W, Kwon S. · Arch Plast Surg (2017)

Small prospective RCT (n=20) of INJECTED PDRN vs saline for diabetic foot ulcers
PDRN significantly improved transcutaneous tissue oxygenation, but the quantitative vessel-density difference was NOT significant (P=0.094)
Supports the angiogenic mechanism while showing some objective endpoints fail to reach significance in small samples (counter-evidence)

View source

5Animal2012

These results suggest that PDRN restores blood flow and tissue architecture, probably by modulating HIF-1α and VEGF expression, and may be an effective therapeutic approach in improving healing of ischemic skin flaps.

Polito F, Bitto A, Galeano M, Irrera N, Marini H, Calò M, Squadrito F, Altavilla D. · J Vasc Surg (2012)

Randomized rat ischemic skin-flap model testing PDRN vs vehicle
PDRN markedly increased blood flow and produced complete re-epithelialization with fibroblast-rich granulation tissue
Effects linked to increased VEGF and adenosine A2A receptor-driven angiogenesis — animal mechanistic support only

View source

6In Vitro2023

PDRN exhibits wound healing and anti-inflammatory activities by activating adenosine A2A receptor and salvage pathways.

Kim TH, Heo SY, Han JS, Jung WK. · Cell Biochem Funct (2023)

In-vitro study confirming the canonical PDRN mechanism: adenosine A2A receptor + salvage pathways underlying wound-healing and anti-inflammatory effects
PDRN reduced nitric oxide/iNOS in stimulated macrophages and promoted fibroblast proliferation and collagen production
Notes commercial PDRN is sourced from salmon/trout DNA (the 'salmon DNA' marketing) — cell-culture, not human or topical evidence

View source

View in Research Library

PDRN / Polynucleotides (topical) Research

Mostly mechanism / observational

The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial.

Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial.

The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review.

Polydeoxyribonucleotide Improves Peripheral Tissue Oxygenation and Accelerates Angiogenesis in Diabetic Foot Ulcers.

Polydeoxyribonucleotide restores blood flow in an experimental model of ischemic skin flaps.

Anti-inflammatory effect of polydeoxyribonucleotides (PDRN) extracted from red alga in macrophages stimulated with lipopolysaccharides: A comparative study with commercial PDRN.